Primary immune thrombocytopenia in adults - disease considerations

Abstract

Introduction. Primary immune thrombocytopenia is a chronic acquired autoimmune disorder that is characterized by isolated thrombocytopenia (<100 x109/L) and the absence of any underlying cause. Treatment of primary immune thrombocytopenia. While splenectomy has a curable potential, it carries long-term risk of infection and thromboembolic complications. Therefore, the use of splenectomy has declined with the advent of rituximab and agonists of thrombopoietin receptors. The efficacy of rituximab is good for the short-term outcome, and the majority of patients will relapse. On the other hand, agonists of thrombopoietin receptors induce remission in only 10-30% of patients after treatment discontinuation, and long-term treatment is often required. Health - related quality of life. Immune thrombocytopenia and its treatments may affect the entire spectrum of patients? lives, encompassing daily activities, emotional health, energy level, fatigue, and work productivity. Primary immune thrombocytopenia World Impact Survey was conducted to discern how immune thrombocytopenia and associated treatments affect patient lives. Concerns about unstable platelet count, low energy levels, inability to exercise, and reduced participation in hobbies and work had the greatest negative impact. While most patients reported ?good health?, nonetheless half of patients reported a negative impact on their emotional well-being that worsened with increasing burden of disease and was often substantial. Conclusion. Although several important improvements have been made in immune thrombocytopenia treatment algorithms, there is still room for improvement. One of the possible options could be early, intensive treatment of immune thrombocytopenia, which might reduce the risk of disease progression and consequently improve patients? quality of life.